Literature DB >> 2834646

Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer.

R A Figlin1, S Piantadosi, R Feld.   

Abstract

We retrospectively analyzed the risk of intracranial recurrence of cancer in 1532 patients who were surgically treated between 1977 and 1986 for Stage I, II, or III non-small-cell lung cancer, after rigorous surgical and pathological staging. This analysis was undertaken as a background for a possible randomized clinical trial of prophylactic cranial irradiation in such patients. One hundred four patients (6.8 percent) had documented first recurrences involving the brain, including 98 patients (6.4 percent) in whom the brain was the sole site of first recurrence. Sixty patients (3.9 percent) had only intracranial involvement at the time of death. Prognostic variables that had a significant effect on the time to recurrence in the brain were histologic features of the carcinoma (patients with nonsquamous-cell cancers were more at risk than those with squamous-cell cancer), the T1N1/T2N0 and T2N1 staging subsets (T1, tumor less than or equal to 3 cm in diameter; T2, tumor greater than 3 cm; N0, no regional lymph-node metastasis; N1, ipsilateral hilar-lymph-node metastasis), and initial weight loss of more than 10 percent. We conclude that prophylactic cranial irradiation would at best benefit only a very small subset of these patients. We believe, therefore, that neither prophylactic cranial irradiation nor a randomized trial is indicated in patients with non-small-cell lung cancer who have undergone complete resection.

Entities:  

Mesh:

Year:  1988        PMID: 2834646     DOI: 10.1056/NEJM198805193182004

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  23 in total

1.  Incidence of brain metastasis in patients with esophageal carcinoma.

Authors:  Ron S Smith; Robert C Miller
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  Preoperative screening for metastases in lung cancer.

Authors:  M F Muers
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

Review 3.  Potential toxicities of prophylactic cranial irradiation.

Authors:  Frank A Giordano; Grit Welzel; Yasser Abo-Madyan; Frederik Wenz
Journal:  Transl Lung Cancer Res       Date:  2012-12

4.  New treatment protocol by intra-operative radiation therapy for metastatic brain tumours.

Authors:  O Nakamura; M Matsutani; N Shitara; K Okamoto; M Kaneko; H Nakamura; A Asai; K Ueki; T Shimizu; Y Tanaka
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

5.  Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial.

Authors:  Xiao-Xiao Dinglin; Yan Huang; Hui Liu; Yin-Duo Zeng; Xue Hou; Li-Kun Chen
Journal:  J Neurooncol       Date:  2013-02-19       Impact factor: 4.130

Review 6.  Radiotherapy in the management of non-small-cell lung cancer.

Authors:  A Bezjak; D Payne
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 7.  Extended resection for higher-stage non-small-cell lung cancer.

Authors:  J D Luketich; D E van Raemdonck; R J Ginsberg
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 8.  Risk factors and management of oligometastatic non-small cell lung cancer.

Authors:  Akshar N Patel; Charles B Simone; Salma K Jabbour
Journal:  Ther Adv Respir Dis       Date:  2016-04-08       Impact factor: 4.031

9.  Incidence and patterns of isolated brain failure in stage III non-small-cell lung cancer treated with concurrent chemoradiation therapy.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Takatoshi Senba; Kotaro Uwatsu; Shogo Oda; Tadaaki Takahashi; Shoji Aono; Shinya Sakai; Takeshi Inoue; Yoshifumi Sugawara
Journal:  Jpn J Radiol       Date:  2009-02-08       Impact factor: 2.374

10.  Can clinical factors be determinants of bone metastases in non-small cell lung cancer?

Authors:  Ahmet Ursavas; Mehmet Karadag; Esra Uzaslan; Erkan Rodoplu; Ezgi Demirdögen; Basak Burgazlioglu; R Oktay Gozu
Journal:  Ann Thorac Med       Date:  2007-01       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.